Assertio Therapeutics Stock News

ASRT vs. STVN: Which Stock Is the Better Value Option?

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Assertio beat on Q2 revenue and earnings and revised guidance upwards. They negotiated debt to save $4.5 million in annual payments.

Here is how Assertio (ASRT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.

Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?

AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pedi

BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.

ASRT vs. CORT: Which Stock Is the Better Value Option?

Includes Full Exercise of Initial Purchaser's Option to Purchase $10 Million of Additional Notes Includes Full Exercise of Initial Purchaser's Option to Purchase $10 Million of Additional Notes

ASRT vs. CORT: Which Stock Is the Better Value Option?

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares jumped 55.2% to close at $0.70 on Tuesday after the company announced it has entered into a global licensing agreement for the development an

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.35% to 32,946.74 while the NASDAQ rose 0.30% to 12,418.54. The